James Meyer, DO
Pulmonary Disease · Fort Dodge, IANPI 1063484228
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,618 of the $2,288 with a category attached, or 70.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 22.9%.
Across 98 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$525
- Boehringer Ingelheim$320
- Harmony Biosciences LLC$283
- GSK$260
- AstraZeneca$167
- Sanofi$157
- plus $577 from 16 others
What the payments were for
- Consulting fees$52523%
- Food & beverage$1,61871%
- Education$1456%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $525 |
| Boehringer Ingelheim | 15 | $320 |
| Harmony Biosciences LLC | 6 | $283 |
| GSK | 22 | $260 |
| AstraZeneca | 8 | $167 |
| Sanofi | 9 | $157 |
| Mylan Specialty L.p. | 8 | $109 |
| Jazz Pharmaceuticals Inc. | 4 | $86 |
| Philips North America LLC | 4 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 3 | $40 |
| Insmed, Inc. | 2 | $34 |
| Pulmonx Corporation | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| United Therapeutics Corporation | 2 | $23 |
| Baxter Healthcare | 1 | $19 |
| 180 Medical, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Electromed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$525
How this compares
$2,288 in reported general payments places this provider in the 55th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 13 | $258,639 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,352 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,327 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,532 |
| Armodafinil | 54 | $1,683 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $1,105 |
| Modafinil | 21 | $1,019 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $552 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $292 |
| Ropinirole Hcl | 16 | $220 |
| Clonazepam | 13 | $117 |
| Zolpidem Tartrate | 50 | $53 |
| Prednisone | 13 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $260 | $38,21267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Fort Dodge
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Brian WittDavenport$19K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
- Neil HorningDes Moines$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.